Page header

Recommendation of the President – Dupixent (dupilumab)

On 26 May 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 73/2026 on the inclusion of the medicinal product Dupixent (dupilumab) in the reimbursement program under the “Treatment of patients with chronic obstructive pulmonary disease (COPD) (ICD-10: J44)” drug program

Publication in Public Information Bulletin (BIP) >>